Reimbursed Care Access in Venezuela

Currently classified as a strictly controlled substance under Venezuela's national drug control framework with no authorized medical use outside of approved clinical research. The country's Ley Orgánica de Drogas implements controls based on the UN drug conventions and limits non‑medical possession, cultivation and distribution; medical/therapeutic access to psilocybin is not established in national practice outside of formal research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Venezuela's legal framework adopts the lists and obligations of the UN psychotropic substances convention and does not provide for routine therapeutic MDMA programs or reimbursement. #

Esketamine (Spravato) is not documented as having a national marketing authorization or a publicly listed routine reimbursement pathway in Venezuela; no publicly available Venezuelan regulatory registration for Spravato was identified in searches of open national/UNODC resources. Ketamine as a chemical class is covered by Venezuela's drug law for legitimate medical use, which provides the legal basis for anesthetic/medical use of ketamine derivatives under regulatory oversight of the Ministry of Health, but specialized, certified delivery programs (as exist for Spravato in other countries) are not documented as established, nor is there evidence of national public-insurer reimbursement for esketamine. For context, esketamine has explicit regulatory status and a restricted distribution/REMS-like program in jurisdictions where it is approved (example: U.S. FDA approval history). #. For international regulatory context on esketamine (example of an approved program outside Venezuela): Spravato approval history. #

Ketamine is an established, legally recognised medicinal anesthetic and analgesic agent and may be lawfully used in Venezuelan medical settings under the country's drug control and pharmaceutical regulations; Venezuela's Ley Orgánica de Drogas explicitly limits controlled substances to quantities necessary for medical treatment and scientific research, which provides the statutory basis for medical ketamine use in hospitals and clinics. #.

In practical terms: ketamine is routinely used worldwide (and in Latin America) as an anesthetic and for emergency medicine; international clinical guidance and research also describe off‑label use of ketamine infusions for treatment‑resistant depression and other psychiatric indications, but such psychiatric indications in Venezuela lack an established, nationwide publicly funded reimbursement program modeled on commercial esketamine delivery programs in some high‑income countries. Where ketamine is used for non‑anesthetic psychiatric indications in Venezuela, access is typically limited to private clinics or hospital programs operating under clinician discretion and local institutional approval; there is no clear publicly published national reimbursement policy guaranteeing coverage for psychiatric ketamine infusion therapy. For general medical/anaesthetic use (surgery, emergency), ketamine is considered a standard medical drug within the legal framework permitting medical use. #, #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Venezuela's control regime adopts UN lists that include N,N‑DMT and related tryptamines; routine therapeutic or reimbursed use is not available. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Venezuela's legal framework follows UN psychotropic substance controls that encompass 5‑MeO‑DMT analogues; no routine medical programs or reimbursement for 5‑MeO‑DMT exist. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Venezuela's drug law and implementing regulations do not provide a framework for routine therapeutic ibogaine use or reimbursement; access would be limited to authorised clinical research if undertaken. #

Ayahuasca (the traditional botanical brew containing DMT) occupies a complex legal space: while the plant materials themselves have cultural and traditional uses in parts of Latin America, the DMT content is controlled under national scheduling. Venezuela's drug control law subjects substances listed under international conventions (including DMT) to control, but enforcement and traditional/ritual practices involving plant preparations can vary locally. There is no formal, nationwide reimbursed medical pathway for ayahuasca; any ritual or traditional use exists in a social/cultural context rather than as an approved reimbursed medical therapy. For statutory control basis see the national drug law implementing UN conventions. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are covered by the country's broadly applied drug control statutes derived from international conventions; there is no routine medical or reimbursed program for mescaline in Venezuela. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. New synthetic phenethylamine psychedelics (e.g., 2C‑B and related 2C‑series compounds) are subject to control under Venezuela's drug law and implementing resolutions that allow the Ministry of Health to list and regulate substances; access is limited to authorised scientific research. #